NANOBIOTIX Reports First Half 2026 Operational and Financial Progress

Nanobiotix, a biotechnology firm specializing in nanotherapeutics, shared updates for H1 2026. The company disclosed early promising results from a Phase 1 study involving JNJ-1900 (NBTXR3) in non-small cell lung cancer. Additionally, successful funding of €86 million in May 2026 bolstered its financial position, securing operations until 2029.

Operationally, JNJ-1900 (NBTXR3) demonstrated effectiveness with no severe adverse events in studies. Notably, the CONVERGE Phase 2 trial, led by Johnson & Johnson, showed encouraging response rates in NSCLC patients. The Phase 3 NANORAY-312 study for head and neck cancer also received a U.S. FDA-approved amendment, optimizing study design.

Financially, Nanobiotix reported €110.9 million in cash and equivalents by end of June 2026. Despite a decrease in total revenues, the firm's strategic financial maneuvers reflect a commitment to advancing innovative cancer therapies.